Suspension of trading

Mirxes Holding Company Limited

2629

KYG6152E1052

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:25 2026-03-31 am EDT			5-day change	1st Jan Change
12.41 ^HKD	-20.24%		-.--%	-71.82%

Apr. 02	Mirxes Holding Company Limited Provides Update on Delay in Publication of the 2025 Annual Results	CI
Mar. 05	Mirxes Holding wins bid for Lianxi gastric cancer screening, early intervention project	RE

Mirxes Plans India Cancer Screening Tie-Up With Apollo Health and Lifestyle

Published on 02/26/2026 at 05:47 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Mirxes Holding Company Limited

Apr. 02	Mirxes Holding Company Limited Provides Update on Delay in Publication of the 2025 Annual Results	CI
Mar. 05	Mirxes Holding wins bid for Lianxi gastric cancer screening, early intervention project	RE
Mar. 05	Mirxes Wins Bid for Gastric Screening Project in China	MT
Feb. 26	Mirxes Plans India Cancer Screening Tie-Up With Apollo Health and Lifestyle	MT
Feb. 26	Mirxes Holding Company Limited Enters into A Memorandum of Understanding with Apollo Health and Lifestyle Limited	CI
Feb. 23	Mirx Holding Company Limited Announces Completion of Enrolment in CADENCE CRC	CI
Feb. 22	229,722,331 Ordinary Shares of Mirxes Holding Company Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2026.	CI
Feb. 10	Mirxes Co-founders, Cornerstone Investors Undertake Voluntary Lock-up of Shares	MT
Feb. 05	Mirxes Nets HK$673 Million via Share Placement	MT
Jan. 28	Mirxes to Raise HK$673 Million via Share Placement; Shares Fall 9%	MT
Jan. 28	Mirxes Holding announces placing 21.9 million shares at HK$32.50/share	RE
Jan. 11	Mirxes Expands Thailand Business With Hospital Partnership, Home Test Launch	MT
Jan. 09	Mirx Holding Company Limited Launches Its New Range of At-Home Screening Test Kits in Thailand	CI
Jan. 09	Mirx Holding Company Limited Enters into A Strategic Partnership with N Health	CI
Dec. 21	Mirxes Holding Company Limited(SEHK:2629) added to S&P Global BMI Index	CI

Chart Mirxes Holding Company Limited

Duration

Period

2629: Dynamic Chart

MiRXES Holding Company Limited is a ribonucleic acid (RNA) technology company that is engaged in providing diagnostic solutions for the early detection of diseases accessible on a global scale. The Company is engaged developing and commercializing non-invasive blood-based microRNA (miRNA) test kits for the early detection of cancer and other diseases. The Company operates through two business segments: Early Detection and Precision Multi-omics segment, and Infectious Diseases segment. The Company offers various disease early detection products (including Core Product GASTROClear) and services, multi-omics candidate discovery and clinical genomic testing through its Early Detection and Precision Multi-omics segment. Its Early Detection product candidates includes LungClear, CRC-1, CADENCE and PHinder. Its Precision Multi-omics focuses on providing complex, miRNA centric multi-omics testing solutions to bio-pharmaceutical companies, and government organizations.

Employees

347

Sector

Biotechnology & Medical Research

More about the company